{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T11:23:33Z","timestamp":1769858613348,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,8,7]],"date-time":"2013-08-07T00:00:00Z","timestamp":1375833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,8,7]],"date-time":"2013-08-07T00:00:00Z","timestamp":1375833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00280-013-2250-6","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T11:24:11Z","timestamp":1375788251000},"page":"909-916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)"],"prefix":"10.1007","volume":"72","author":[{"given":"Hielke J.","family":"Meulenbeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young E.","family":"Whang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl H.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthe S.","family":"Zandvliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot W.","family":"Ebbinghaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Hudes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,7]]},"reference":[{"key":"2250_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513\u20131520","journal-title":"N Engl J Med"},{"key":"2250_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0022-5347(05)00034-0","volume":"175","author":"JS Lam","year":"2006","unstructured":"Lam JS, Leppert JT, Vemulapalli SN et al (2006) Secondary hormonal therapy for advanced prostate cancer. J Urol 175:27\u201334","journal-title":"J Urol"},{"key":"2250_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/156800909787580999","volume":"9","author":"TM Morgan","year":"2009","unstructured":"Morgan TM, Koreckij TD, Corey E (2009) Targeted therapy for advanced prostate cancer: inhibition of the PI3K\/Akt\/mTOR pathway. Curr Cancer Drug Targets 9:237\u2013249","journal-title":"Curr Cancer Drug Targets"},{"key":"2250_CR4","first-page":"4997","volume":"57","author":"P Cairns","year":"1997","unstructured":"Cairns P, Okami K, Halachmi S et al (1997) Frequent inactivation of PTEN\/MMAC1 in primary prostate cancer. Cancer Res 57:4997\u20135000","journal-title":"Cancer Res"},{"key":"2250_CR5","first-page":"636","volume":"9","author":"L Elit","year":"2006","unstructured":"Elit L (2006) Drug evaluation: AP-23573-an mTOR inhibitor for the treatment of cancer. IDrugs 9:636\u2013644","journal-title":"IDrugs"},{"key":"2250_CR6","doi-asserted-by":"publisher","first-page":"7106","DOI":"10.1038\/onc.2008.318","volume":"27","author":"Y Wang","year":"2008","unstructured":"Wang Y, Mikhailova M, Bose S, Pan CX, de Vere White RW, Ghosh PM (2008) Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 27:7106\u20137117","journal-title":"Oncogene"},{"key":"2250_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1158\/1535-7163.MCT-07-0581","volume":"7","author":"A Schayowitz","year":"2008","unstructured":"Schayowitz A, Sabnis G, Njar VCO, Brodie AMH (2008) Synergistic effect of a novel antiandrogen, VN\/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther 7:121\u2013132","journal-title":"Mol Cancer Ther"},{"key":"2250_CR8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3892\/ijo.2012.1487","volume":"41","author":"RM Squillace","year":"2012","unstructured":"Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM (2012) Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol 41:425\u2013432","journal-title":"Int J Oncol"},{"key":"2250_CR9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","volume":"116","author":"S Sonis","year":"2010","unstructured":"Sonis S, Treister N, Chawla S, Demtri G, Haluska F (2010) Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116:210\u2013215","journal-title":"Cancer"},{"key":"2250_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2250_CR11","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","volume":"25","author":"AJ Armstrong","year":"2007","unstructured":"Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al (2007) Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25:3965\u20133970","journal-title":"J Clin Oncol"},{"key":"2250_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/djj129","volume":"98","author":"DP Petrylak","year":"2006","unstructured":"Petrylak DP, Ankerst DP, Jiang CS et al (2006) Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98:516\u2013521","journal-title":"J Natl Cancer Inst"},{"key":"2250_CR13","first-page":"47","volume":"16","author":"CS Cleeland","year":"1990","unstructured":"Cleeland CS (1990) Assessment of pain in cancer: measurement issues. Adv Pain Res Ther 16:47\u201355","journal-title":"Adv Pain Res Ther"},{"key":"2250_CR14","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148\u20131159","journal-title":"J Clin Oncol"},{"key":"2250_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11523-009-0107-z","volume":"4","author":"K Sankhala","year":"2009","unstructured":"Sankhala K, Mita A, Kevin Kelly K et al (2009) The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Targ Oncol 4:135\u2013142","journal-title":"Targ Oncol"},{"key":"2250_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2006","unstructured":"Atkins MB, Hidalgo M, Stadler WM et al (2006) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909\u2013918","journal-title":"J Clin Oncol"},{"key":"2250_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","volume":"26","author":"MM Mita","year":"2008","unstructured":"Mita MM, Mita AC, Chu QS et al (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573;MK-8669) administered intravenously daily for 5\u00a0days every 2\u00a0weeks to patients with advanced malignancies. J Clin Oncol 26:361\u2013367","journal-title":"J Clin Oncol"},{"key":"2250_CR18","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1158\/1078-0432.CCR-08-2076","volume":"15","author":"CM Hartford","year":"2009","unstructured":"Hartford CM, Desai AA, Janisch L et al (2009) A Phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 15:1428\u20131434","journal-title":"Clin Cancer Res"},{"key":"2250_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1177\/0091270007306957","volume":"47","author":"J Boni","year":"2007","unstructured":"Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L (2007) Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol 47:1430\u20131439","journal-title":"J Clin Pharmacol"},{"key":"2250_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1067\/mcp.2001.112513","volume":"69","author":"Y B\u00f6ttiger","year":"2001","unstructured":"B\u00f6ttiger Y, S\u00e4we J, Brattstr\u00f6m C et al (2001) Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther 69:32\u201340","journal-title":"Clin Pharmacol Ther"},{"key":"2250_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2165\/00002018-199716040-00004","volume":"16","author":"C Mignat","year":"1997","unstructured":"Mignat C (1997) Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 16:267\u2013278","journal-title":"Drug Saf"},{"key":"2250_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2165\/00003088-200443130-00003","volume":"43","author":"ID Cockshott","year":"2004","unstructured":"Cockshott ID (2004) Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinetics 43:855\u2013878","journal-title":"Clin Pharmacokinetics"},{"key":"2250_CR23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1158\/0008-5472.CAN-10-2314","volume":"71","author":"MC Hodgson","year":"2011","unstructured":"Hodgson MC, Shao LJ, Frolov A et al (2011) Decreased expression and androgen regulation of the tumour suppressor gene INPP4B in prostate cancer. Cancer Res 71:572\u2013582","journal-title":"Cancer Res"},{"key":"2250_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","volume":"19","author":"DJ Mulholland","year":"2011","unstructured":"Mulholland DJ, Tran LM, Li Y et al (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19:792\u2013804","journal-title":"Cancer Cell"},{"key":"2250_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575\u2013586","journal-title":"Cancer Cell"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2250-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-013-2250-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2250-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2250-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T02:58:13Z","timestamp":1715828293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-013-2250-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["2250"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2250-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,7]]},"assertion":[{"value":"28 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}